AeroFact (AP-002) / Aerogen Pharma, Nuance Biotech - LARVOL DELTA

APC-AF-CLN-003: Safety and Efficacy of AeroFact in Preterm Infants With Respiratory Distress Syndrome (clinicaltrials.gov) - P3 | N=260 | Not yet recruiting | Sponsor: Aerogen Pharma Limited | Trial completion date: Aug 2027 ➔ May 2029 | Initiation date: Apr 2025 ➔ Aug 2025 | Trial primary completion date: Aug 2026 ➔ May 2027

Trial completion date • Trial initiation date • Trial primary completion date • Acute Respiratory Distress Syndrome • Respiratory Diseases

Safety and Efficacy of AeroFact in Preterm Infants With Respiratory Distress Syndrome (clinicaltrials.gov) - P3 | N=260 | Not yet recruiting | Sponsor: Aerogen Pharma Limited

New P3 trial • Acute Respiratory Distress Syndrome • Respiratory Diseases

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact (clinicaltrials.gov) - P2 | N=261 | Completed | Sponsor: Aerogen Pharma Limited | Active, not recruiting ➔ Completed

Trial completion • Acute Respiratory Distress Syndrome • Respiratory Diseases

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact (clinicaltrials.gov) - P2 | N=261 | Active, not recruiting | Sponsor: Aerogen Pharma Limited | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Respiratory Distress Syndrome • Respiratory Diseases